Recently published results of a GDNF intraputaminal infusion clinical trial

Posted on by Phil Franchina

A clinical trial, is by definition an experiment or a test — an effort to determine if something works,...see more or doesn’t.  Sometimes, although the intended outcome of a clinical trial may fall short of expectations, the results are nevertheless intriguing and may spark additional avenues of investigation. Such is the case in a clinical trial […]

Read More

Spotlight on Dr. Giulietta Riboldi

Posted on by Phil Franchina

Spotlight on Dr. Giulietta Roboldi Giulietta Riboldi, PhD, a post-doctoral fellow at the Marlene and Paolo Fresco Institute for Parkinson’s...see more disease and Movement Disorders at NYU Langone Health, is the recipient of a 2018 APDA Post-Doctoral Fellowship for her work studying how mutations in a protein called glucocerebrosidase (GBA) mutations lead to the development Parkinson’s disease (PD).

Read More

Marijuana & PD

Posted on by Phil Franchina

Marijuana & PD While the medications that doctors prescribe for PD can be helpful, there remain gaps in what the...see more medications can treat. Some people with PD are eager to find alternative methods to help their symptoms and look into whether other therapies, such as medical marijuana, also known as medical cannabis, can be useful.

Read More

FDA Approves Inbrija™ (levodopa inhalation powder) Parkinson’s disease

Posted on by Phil Franchina

FDA Approves Inbrija™ (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJA™ (levodopa inhalation powder)...see more for the treatment of OFF periods in people with Parkinson’s disease (PD) taking carbidopa/levodopa. INBRIJA™ is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […]

Read More